nadp has been researched along with Diabetic Angiopathies in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Mello, WC | 1 |
| Cai, L; Hein, DW; Li, X; Marshall, JP; Prabhu, SD; Xiang, X; Zhou, G | 1 |
| Ceriello, A | 1 |
| Asahina, T; Harada, N; Ikebuchi, M; Kashiwagi, A; Kikkawa, R; Nishio, Y; Saeki, Y; Shigeta, Y; Takagi, Y; Tanaka, Y | 1 |
| Duckworth, WC | 1 |
| Liaudet, L; Mabley, J; Pacher, P; Soriano, FG; Szabó, C | 1 |
| Voskresenskiĭ, ON | 1 |
3 review(s) available for nadp and Diabetic Angiopathies
| Article | Year |
|---|---|
Possible role of oxidative stress in the pathogenesis of hypertension.
Topics: Antihypertensive Agents; Antioxidants; Diabetic Angiopathies; Humans; Hypertension; Incidence; NADP; Oxidative Stress; Reactive Oxygen Species | 2008 |
Hyperglycemia and cardiovascular disease.
Topics: Blood Glucose; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Diabetic Angiopathies; Glycation End Products, Advanced; Humans; Hyperglycemia; NADP; Oxidative Stress; Postprandial Period; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Risk Factors | 2001 |
[Pancreatic hormones and arteriosclerosis].
Topics: Aging; Animals; Arteriosclerosis; Blood Proteins; Cholesterol; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dogs; Fatty Acids; Fatty Liver; Glucagon; Guinea Pigs; Hypercholesterolemia; Insulin; Insulin Secretion; Lipotropic Agents; NADP; Obesity; Pancreatectomy; Phosphatidylcholines; Rabbits; Rats; Sterols; Tissue Extracts | 1967 |
4 other study(ies) available for nadp and Diabetic Angiopathies
| Article | Year |
|---|---|
Metallothionein reverses the harmful effects of angiotensin II on the diabetic heart.
Topics: Angiotensin II; Cardiomyopathies; Diabetic Angiopathies; Humans; Metallothionein; NADP; Oxidative Stress | 2008 |
Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart.
Topics: Angiotensin II; Animals; Apoptosis; Cardiomyopathies; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Fibrosis; Hypertrophy; Metallothionein; Mice; Mice, Transgenic; Myocardium; Myocytes, Cardiac; NADP; Oxidative Stress; Ventricular Remodeling | 2008 |
Impaired activation of glucose oxidation and NADPH supply in human endothelial cells exposed to H2O2 in high-glucose medium.
Topics: Adenosine Triphosphate; Cells, Cultured; Culture Media; Diabetic Angiopathies; Endothelium, Vascular; Glucose; Glucose-6-Phosphate; Glucosephosphate Dehydrogenase; Glucosephosphates; Glutathione; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Hydrogen Peroxide; Intracellular Fluid; Lactates; Lactic Acid; NAD; NADP; Oxidation-Reduction; Oxidative Stress; Pentose Phosphate Pathway; Phosphofructokinase-1 | 1995 |
Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase.
Topics: Adenosine Triphosphate; Administration, Oral; Animal Diseases; Animals; Aorta, Thoracic; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Disease Progression; Endothelium, Vascular; Enzyme Inhibitors; Glycated Hemoglobin; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; NADP; Phenanthrenes; Poly(ADP-ribose) Polymerase Inhibitors; Streptozocin; Vasoconstrictor Agents; Vasodilator Agents; Vasomotor System | 2001 |